Pluri Inc.

Pluri Inc. Secures Nasdaq Listing: A Critical Update for Investors

Pluri Inc. recently delivered crucial news for its investors: the company has successfully resolved its Nasdaq listing concerns, ensuring its continued presence on the exchange. This significant development provides clarity and stability, removing a major uncertainty for shareholders.

1. Nasdaq Compliance Achieved

Pluri Inc. has successfully regained compliance with Nasdaq's minimum market value requirement, resolving a potential delisting issue. Nasdaq officially confirmed that Pluri met the necessary criteria, closing the matter. This means the company's shares will continue to trade on the Nasdaq Capital Market.

2. Event Date/Timeline

Pluri received official notification from Nasdaq on February 27, 2026, confirming its compliance. The company publicly reported this positive development on March 2, 2026. Pluri demonstrated sustained compliance from February 13 to February 26, 2026.

3. Background: Why This Was Critical

Nasdaq requires companies to maintain a minimum market value of $35 million for their listed securities (per Listing Rule 5550(b)(2)). On January 20, 2026, Pluri received a warning letter from Nasdaq because its market value had fallen below this threshold, and it did not meet any alternative financial requirements. Broader market challenges and specific operational hurdles contributed to this decline in market value, impacting the company's valuation. To avoid delisting, Pluri needed to maintain a market value above $35 million for at least 10 consecutive business days, a condition it successfully met during the specified compliance period.

4. Impact Assessment: Significance for Pluri and Investors

Maintaining a Nasdaq listing is paramount for any public company. This successful resolution offers several key benefits:

• Enhances Credibility: It reaffirms Pluri's standing as a legitimate, compliant public company.
• Ensures Investor Access: It guarantees continued liquidity and accessibility for investors to trade Pluri's stock on a major exchange.
• Removes Uncertainty: It eliminates a significant risk that could have severely impacted the company's share price and ability to raise capital. This stability allows Pluri to focus on its core strategic objectives.

5. Impact Assessment: Across Stakeholders

This positive news benefits various groups connected to Pluri:

• Investors: As primary beneficiaries, investors see the risk of delisting and its associated negative impacts on liquidity and valuation removed.
• Employees: It boosts morale and job security, signaling a more stable future for the company.
• Customers & Partners: It reinforces confidence in Pluri's long-term viability and operational stability.

6. Financial Impact

While regaining compliance does not have an immediate, quantifiable positive financial impact in terms of revenue or profit, it is crucial for the company's financial health and stability. The successful resolution of the delisting issue provides crucial financial benefits:

• Preserves Shareholder Value: It prevents the potential significant erosion of shareholder value that typically accompanies a delisting, which can lead to reduced liquidity and a lower trading price on over-the-counter markets.
• Maintains Access to Capital Markets: It ensures Pluri Inc. retains its ability to access broader capital markets for potential future equity or debt financing, vital for funding its research and development initiatives and operational needs. Delisting would severely restrict these options.
• Avoids Increased Administrative Costs: It prevents the additional administrative and legal costs associated with navigating an over-the-counter market and potentially seeking relisting in the future.

Pluri believes that maintaining its Nasdaq listing is fundamental to its long-term financial strategy and its ability to attract and retain institutional investors.

7. Looking Ahead: Pluri's Strategic Focus

With the delisting threat behind it, Pluri Inc., a biotechnology company focused on developing cell-based therapies for regenerative medicine, can now fully concentrate on its strategic initiatives. While compliance is a positive step, investors should recognize that the underlying factors contributing to the previous low market value may still require attention. Pluri's future success will depend on its ability to:

• Advance its Product Pipeline: Achieve key milestones in clinical development and regulatory approvals for candidates like PLX-R18.
• Strengthen Financial Performance: Improve revenue generation, manage operational costs, and secure necessary funding to support its research and development.
• Execute Business Strategy: Pursue strategic partnerships, expand market reach, or innovate within its sector.

The company will need to consistently demonstrate financial health and market support to sustain its market value above the Nasdaq threshold.

8. Key Takeaways for Investors

• Risk Reduction, Not Growth Catalyst: This news primarily removes a significant downside risk rather than signaling an immediate growth catalyst.
• Focus on Fundamentals: Investors should now shift their attention to Pluri's core business performance. Monitor upcoming earnings reports for details on revenue trends, cash position, progress in its clinical trials for lead candidates, and overall financial health.
• Ongoing Risks: While delisting is resolved, investors should remain aware of other inherent risks in the biotechnology sector, such as clinical trial outcomes, regulatory hurdles, competition, and the need for future capital.
• Informed Decisions: Always conduct thorough due diligence and align investment decisions with your personal financial goals and risk tolerance.